We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a recent warning letter to Baxter Healthcare, the FDA stated it found the company’s responses to an inspection of its dialysis manufacturing plant to be inadequate because Baxter failed to include supporting documentation regarding the corrective actions it has taken.